158 related articles for article (PubMed ID: 20697965)
1. What happens after an elevated PSA test: the experience of 13,591 veterans.
Zeliadt SB; Hoffman RM; Etzioni R; Ginger VA; Lin DW
J Gen Intern Med; 2010 Nov; 25(11):1205-10. PubMed ID: 20697965
[TBL] [Abstract][Full Text] [Related]
2. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
Hudson MA; Luo S; Chrusciel T; Yan Y; Grubb RL; Carson K; Scherrer JF
Urol Oncol; 2014 Jan; 32(1):34.e9-18. PubMed ID: 23506962
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
4. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
5. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
6. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
Caster JM; Falchook AD; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Care Cascades Following Low-Value Prostate-Specific Antigen Testing Among Veterans Dually Enrolled in the US Veterans Health Administration and Medicare Systems.
Pickering AN; Zhao X; Sileanu FE; Lovelace EZ; Rose L; Schwartz AL; Oakes AH; Hale JA; Schleiden LJ; Gellad WF; Fine MJ; Thorpe CT; Radomski TR
JAMA Netw Open; 2022 Dec; 5(12):e2247180. PubMed ID: 36520431
[TBL] [Abstract][Full Text] [Related]
8. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice.
Gaylis FD; Choi JE; Hamilton Z; Dato P; Cohen E; Calabrese R; Prime H; Rosenbaum A; Kader AK
Urol Oncol; 2017 Nov; 35(11):663.e1-663.e7. PubMed ID: 28736250
[TBL] [Abstract][Full Text] [Related]
9. Early diagnosis of prostate cancer in the Western Cape.
Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
[TBL] [Abstract][Full Text] [Related]
10. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
11. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of delayed clinician response to elevated prostate-specific antigen values.
Nepple KG; Joudi FN; Hillis SL; Wahls TL
Mayo Clin Proc; 2008 Apr; 83(4):439-45. PubMed ID: 18380989
[TBL] [Abstract][Full Text] [Related]
13. The Relationship of Baseline Prostate Specific Antigen and Risk of Future Prostate Cancer and Its Variance by Race.
Verges DP; Dani H; Sterling WA; Weedon J; Atallah W; Mehta K; Schreiber D; Weiss JP; Karanikolas NT
J Natl Med Assoc; 2017 Spring; 109(1):49-54. PubMed ID: 28259216
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.
Crook JM; Bahadur YA; Bociek RG; Perry GA; Robertson SJ; Esche BA
Cancer; 1997 Jan; 79(2):328-36. PubMed ID: 9010106
[TBL] [Abstract][Full Text] [Related]
15. Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health Administration.
Radomski TR; Huang Y; Park SY; Sileanu FE; Thorpe CT; Thorpe JM; Fine MJ; Gellad WF
J Am Geriatr Soc; 2019 Sep; 67(9):1922-1927. PubMed ID: 31276198
[TBL] [Abstract][Full Text] [Related]
16. The results of radical prostatectomy at a community hospital during the prostate specific antigen era.
Smitt MC; Heltzel M
Cancer; 1996 Mar; 77(5):928-33. PubMed ID: 8608486
[TBL] [Abstract][Full Text] [Related]
17. Bone scan overuse in staging of prostate cancer: an analysis of a Veterans Affairs cohort.
Palvolgyi R; Daskivich TJ; Chamie K; Kwan L; Litwin MS
Urology; 2011 Jun; 77(6):1330-6. PubMed ID: 21492911
[TBL] [Abstract][Full Text] [Related]
18. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study.
Palsdottir T; Nordstrom T; Karlsson A; Grönberg H; Clements M; Eklund M
BMJ Open; 2019 Mar; 9(3):e027958. PubMed ID: 30928965
[TBL] [Abstract][Full Text] [Related]
19. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
20. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
